8月10日到15日，全球医药市场共完成了六项授权和合作协议。中国医药市场完成3项，包括2项引进和1项出海交易。其中最引人注目的交易是华东医药引进Imbiologics 公司资产IMB-101 和 IMB-102 ，首付600万美元，总金额3.16亿美元。
在全球范围内，本周签署了三项协议。值得关注的交易是ArriVent BioPharma对与Aarvik Therapeuticsk合作开发的抗体偶联药物（ADC）项目行使独家选择权，潜在金额高达1亿美元。
From August 10 to 15, six licensing and cooperation agreements were finalized globally. Within China's biotech industry, three significant deals were completed. The top transaction of the week was an in-licensing agreement between Imbiologics and Huadong Medicine for IMB-101 and IMB-102, valued at $316 million, with an upfront payment of $6 million.
On the global stage, three agreements were signed this week. The noteworthy deal is ArriVent BioPharma's exercise of an exclusive option to collaborate with AarvikTherapeutics on the development of an antibody-drug conjugate (ADC) program, with a potential value of up to $100 million.
2b. Global section
3. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
